E
Sell
3/14/2023Downgrade
Curative Biotechnology, Inc. (CUBT) was downgraded to E+ from D on 3/14/2023 due to a decline in the total return index.
D
Sell
2/9/2023Upgraded
Curative Biotechnology, Inc. (CUBT) was upgraded to D from E+ on 02/09/2023.
E
Sell
2/8/2023Downgrade
Curative Biotechnology, Inc. (CUBT) was downgraded to E+ from D on 2/8/2023 due to a decline in the total return index.
D
Sell
11/25/2022Upgraded
Curative Biotechnology, Inc. (CUBT) was upgraded to D from D- on 11/25/2022.
D
Sell
9/2/2022Upgraded
Curative Biotechnology, Inc. (CUBT) was upgraded to D- from on 9/2/2022 due to a significant increase in the total return index, growth index and volatility index. Operating cash flow increased 73.8% from -$1.19M to -$310.7, EBIT increased 25.23% from -$1.29M to -$963.4, and earnings per share increased from -$0.0024 to -$0.0023.
